MedPath

Veradermics, Inc.

Veradermics, Inc. logo
๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Holding
Established
2019-10-01
Employees
1
Market Cap
-
Website
http://www.veradermics.com

Clinical Trials

5

Active:2
Completed:1

Trial Phases

3 Phases

Phase 2:3
Phase 3:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)โ€ข Click on a phase to view related trials

Phase 2
3 (60.0%)
Not Applicable
1 (20.0%)
Phase 3
1 (20.0%)

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

Not Applicable
Recruiting
Conditions
Androgenetic Alopecia (AGA)
Androgenetic Alopecia
AGA
Female Androgenetic Alopecia
Hair Loss
Interventions
Drug: VDPHL01 BID
Drug: VDPHL01 QD
Drug: Placebo
First Posted Date
2025-08-28
Last Posted Date
2025-08-28
Lead Sponsor
Veradermics, Inc.
Target Recruit Count
552
Registration Number
NCT07146022
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Site 73, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site 89, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site 77, Phoenix, Arizona, United States

and more 63 locations

Safety and Efficacy of VDPHL01 in Males With AGA

Phase 3
Recruiting
Conditions
Androgenetic Alopecia
AGA
Male Pattern Baldness
Interventions
Drug: Placebo
First Posted Date
2025-05-14
Last Posted Date
2025-07-14
Lead Sponsor
Veradermics, Inc.
Target Recruit Count
480
Registration Number
NCT06972264
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Site 89, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site 77, Phoenix, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site 93, Northridge, California, United States

and more 38 locations

Efficacy and Safety of VDPHL01 in Males With AGA

Phase 2
Active, not recruiting
Conditions
Androgenetic Alopecia
AGA
Male Pattern Baldness
Interventions
Drug: Placebo
First Posted Date
2024-12-09
Last Posted Date
2025-09-03
Lead Sponsor
Veradermics, Inc.
Target Recruit Count
480
Registration Number
NCT06724614
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Site 36, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site 28, Phoenix, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site 30, Fort Smith, Arkansas, United States

and more 41 locations

Safety and Efficacy of VDPHL01 in Males and Females With AGA

Phase 2
Active, not recruiting
Conditions
Androgenetic Alopecia
AGA
Male Pattern Baldness
Interventions
First Posted Date
2024-07-30
Last Posted Date
2025-09-03
Lead Sponsor
Veradermics, Inc.
Target Recruit Count
70
Registration Number
NCT06527365
Locations
๐Ÿ‡บ๐Ÿ‡ธ

01, San Diego, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

04, New Albany, Indiana, United States

๐Ÿ‡บ๐Ÿ‡ธ

03, Hackensack, New Jersey, United States

and more 1 locations

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

Phase 2
Completed
Conditions
Common Wart
Verruca Vulgaris
Warts
Interventions
Drug: VDMN-21 Patch Low Dose
Drug: VDMN-21 Patch High Dose
Drug: Vehicle Patch
First Posted Date
2023-04-05
Last Posted Date
2025-05-08
Lead Sponsor
Veradermics, Inc.
Target Recruit Count
153
Registration Number
NCT05799157
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Site 07, Fort Smith, Arkansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site 16, San Diego, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Site 02, Plainfield, Indiana, United States

and more 13 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.